Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

References

• Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535-40
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers. Pharmacoeconomics 2008;26:149-62
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd edn. Am J Psychiatry 2004;161(2 Suppl):1-56
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
   PubMed Web of Science ®Google Scholar
• Moore TA. Schizophrenia treatment guidelines in the United States. Clin Schizophr Relat Psychoses 2011;5:40-9
   Google Scholar
• International Psychopharmacology Algorithm Project. Schizophrenia Algorithm: Side Effects of Antipsychotics. http://www.ipap.org/schiz/index.php?screen=side_effects, Accessed April 12, 2012
   Google Scholar
• McEvoy JP, Scheifler PL, Frances A. Expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(11 Suppl):1-80
   Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
   PubMed Web of Science ®Google Scholar
• Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010;117:75-82
   PubMed Web of Science ®Google Scholar
• Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med 2007;74:597-606
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-7
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21 . http://www.biomedcentral.com/1741-7015/3/21
   PubMed Web of Science ®Google Scholar
• Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32:724-42
   PubMed Web of Science ®Google Scholar
• Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010;71:304-11
   PubMed Web of Science ®Google Scholar
• Latuda (lurasidone HCl) tablets [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc. May 2012
   Google Scholar
• Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacol (Berl) 2013;225:519-30
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:829-36
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168:957-67
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47:670-7
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013;145:101-9
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind non-inferiority study. Schizophr Res 2013;147:95-102
   Google Scholar
• Abouzaid S, Jutkowitz E, Foley KA, et al. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag 2010;13:247-54
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Bureau of Labor Statistics. Consumer Price Index, All Urban Consumers. http://data.bls.gov/cgi-bin/surveymost?cu, Accessed October 23, 2012
   Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not repond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10
   Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention: a double-blind, placebo-controlled study (PEARL 3). Poster presented at: American Psychiatric Association; May 5-9, 2012; Philadelphia, PA
   Google Scholar
• D’Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices–Part 2. Value Health 2011;14:429-37
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny A, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
   PubMed Web of Science ®Google Scholar
• Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharm 2012a;27:165-76
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189:259-66
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
   PubMed Web of Science ®Google Scholar
• McDermott S, Moran R, Platt T, et al. Heart disease, schizophrenia, and affective psychoses: epidemiology of risk in primary care. Community Ment Health J 2005;41:747-55
   PubMedGoogle Scholar
• Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-11
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, O’Day K, Meyer K, et al. Time-on-Therapy for atypical antipsychotics in a Markov Cohort Analysis. Poster presented at: ISPOR Annual International Meeting; June 2-6, 2012; Washington DC
   Google Scholar
• Arias E. United States life tables, 2007. National vital statistics reports; vol 59 no 9. Hyattsville, MD: National Center for Health Statistics, 2011
   Google Scholar
• Hor K, Taylor M. Review: suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010;24:81-90
   PubMed Web of Science ®Google Scholar
• O’Sullivan AK, Rubin J, Nyambose J, et al. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics 2011;29:693-704
   PubMed Web of Science ®Google Scholar
• Red Book Online. Micromedex 2.0. Thomson Reuters. http://www.micromedexsolutions.com Accessed October 23, 2012
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Llorente MD, Urrutia V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes 2006;24:18-24
   Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011;168:947-56
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012b;13:1599-613
   PubMed Web of Science ®Google Scholar
• Data on File [lurasidone HCl, NDA 200603, Clinical Study Report D1050229E]. Fort Lee, NJ: Sunovion Pharmaceuticals Inc. 2011-2012
   Google Scholar
• Data on File [lurasidone HCl, NDA 200603, Clinical Study Report D1050231E]. Fort Lee, NJ: Sunovion Pharmaceuticals Inc. 2011-2012
   Google Scholar
• Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with luradisone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry http://dx.doi/org:10.4088/JCP.12m08084. 2013;74:507-15 [Epub ahead of print]
   Google Scholar
• Data on File [lurasidone HCl, NDA 200603, Clinical Study Report D1001048]. Fort Lee, NJ: Sunovion Pharmaceuticals Inc. 2011-2012
   Google Scholar